Please assess the completion status of the following clinical trial:

Trial Title: EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: over 18 or 18 years old, less than 75 years old;~* Patents with myocardial infarction who have symptom onset within 6h before randomization;~* ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ;~* Patents with an expected PCI-related delay \[expected time delay from FMC to first balloon dilation≥90 min, and difference between the time of FMC to balloon dilation minus the time from FMC to start of fibrinolysis ≥60 minutes)\];~* Signed informed consent form prior to trial participation.~Exclusion Criteria:~1. Evidence of cardiac rupture;~2. ECG: new left bundle branch block;~3. Diagnosis to balloon inflation time over 3 hours;~4. Thrombolysis contradictions:~   * Definite cerebral apoplexy history;~  * Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \< 3 months);~  * Active bleeding or known bleeding disorder/diathesis;~  * Recent administration of any i.v. or s.c. anticoagulation within 12 hours including unfractionated heparin, enoxaparin and/or bivalirudin or current use of oral anticoagulation(warfarin or coumadin);~  * Uncontrolled hypertension, defined as a single blood pressure measurement ≥ 180/110 mm Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to randomisation;~  * Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction); Prolonged or traumatic cardiopulmonary resuscitation (\> 10 minutes) within the past 2 Weeks Major surgery pending in the following 30 days;~5. Severe complication~   * Other diseases with life expectancy ≤12 months;~  * Any history of Severe renal or hepatic dysfunction(hepatic failure, cirrhosis, portal hypertension and active hepatitis); Neutropenia, thrombocytopenia ; Known acute pancreatitis;~  * Known acute pericarditis and/or subacute bacterial endocarditis;~  * Arterial aneurysm, arterial/venous malformation and aorta dissection;~6. Complex heart condition~   * Cardiogenic shock(SBP \<90 mmHg after fluid infusion or SBP\<100 mmHg after vasoactive drugs);~  * PCI within previous 1 month or Previous coronary-artery bypass surgery(CABG);~  * Previously known multivessel coronary artery disease not suitable for revascularization;~  * Hospitalisation for cardiac reason within past 48 hours;~7. Not suitable for clinical trial~   * Inclusion in another clinical trial;~  * Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days;~  * Pregnancy or lactating;~  * Body weight \<40kg or \>125kg;~  * Known hypersensitivity to any drug that may appear in the study;~  * Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Early post-fibrinolytic catheterisation (Type: EXPERIMENTAL): For STEMI Patients, alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.Early routine catheterization after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
- Primary PCI (Type: OTHER): For STEMI Patients,primary PCI is performed without fibrinolytic therapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).